Business UpdateAug 10, 2026, 08:07 AM
Telomir-Zn Preclinical Data Published, Supports Phase 1/2 TNBC Trial
AI Summary
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn in the Journal of Oncology Research and Therapy. The study demonstrates Telomir-Zn's ability to suppress tumor growth in prostate and triple-negative breast cancer (TNBC) models by selectively modulating intracellular iron and copper, inhibiting KDM enzymes, and reactivating tumor-suppressor genes. These findings provide strong scientific foundation for advancing Telomir-Zn to a planned Phase 1/2 clinical trial in TNBC, addressing a significant unmet need in oncology.
Key Highlights
- Telomir-Zn preclinical data published in Journal of Oncology Research and Therapy.
- Suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models.
- Mechanism: Selectively modulates intracellular iron and copper, inhibiting KDM enzymes.
- Anti-cancer activity proven dependent on iron depletion, reversing with iron addition.
- Selectively killed cancer cells at low concentrations, sparing normal cells at 50x higher.
- Reactivated tumor-suppressor genes (STAT1, GSTP1, RASSF1A, CDKN2A, MASPIN).
- Reduced primary tumor size and metastatic dissemination in TNBC xenograft models.
- Supports advancement to planned Phase 1/2 clinical trial in TNBC.
Price Impact
More from TELO